The movement of the management of mental illness to community settings has provided an opportunity for persons with serious mental illness to engage in sexual activities, which often results in pregnancy. The need for psychotropic medication during pregnancy and lactation must be weighted against the possible teratogenic organic and behavioral effects of these drugs. A review of the literature presents the risk and benefit considerations of psychotropic drugs to inform care of pregnant and lactating mentally ill women. Although some psychotropic medications are clearly associated with teratogenic effects for offspring, many psychotropic drugs demonstrate no relationship with ill effects. Mental illness, pregnancy, and lactation can be managed in a safe manner if the clinician is knowledgeable about specific teratogenic drug effects and assists the client to make appropriate decisions.
Get full access to this article
View all access options for this article.
References
1.
Altshuler, L. L., Cohen, L., Szuba, M. P., Burt, V. K., Gitlin, M., & Mintz, J. (1996). Pharmacologic management of psychiatric illness in pregnancy: Dilemmas and guidelines. American Journal of Psycbiatry, 153, 592-606.
2.
American Academy of Pediatrics, Committee on Drugs. (1994). The transfer of drugs and other chemicals into human milk. Pediatrics, 93, 137-150.
3.
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
4.
Ananth, J. (1975). Congenital malformations with psychopharmacologic agents. Comprehensive Psychiatry, 16, 437-445.
5.
Apfel, R. J., & Handel, M. H. (1993). Madness and loss of motherbood. Washington, DC: American Psychiatric Press.
6.
Aruffo, J. G., Coverdale, J. H., Chacko, R. C., & Dworkin, R. J. (1990). Knowledge about AIDS among women psychiatric outpatients. Hospital and Community Psychiatry, 41, 326-328.
7.
Beeley, L. (1986). Adverse affects of drugs in later pregnancy. Clinical Obstetrics and Gynecology, 13, 197-214.
8.
Bergman, U., Rosa, F. W., Baum, C., Bengt-Erik, W., & Faich, G. A. (1992). Effect of exposure to benzodiazepine during fetal life. Lancet, 340, 694-696.
9.
Buist, A., Norman, T. R., & Dinnerstein, L. (1990). Breastfeeding and the use of psychotropic medication: A review. Journal of Affective Disorders, 19, 197-206.
10.
Casiano, M. E., & Hawkins, D. R. (1987). Major mental illness and childbearing. Psychiatric Clinics of North America, 10, 35-51.
11.
Cohen, L. S., Friedman, J. M., Jefferson, J. W., Johnson, E. M., & Weiner, M. L. (1994). A reevaluation of risk of in utero exposure to lithium. Journal of the American Medical Association, 271, 146-150.
12.
Coverdale, J. H., & Aruffo, J. A. (1989). Family planning needs of female chronic psychiatric outpatients. American Journal of Psychiatry, 146, 1489-1491.
13.
Coverdale, J., Aruffo, J., & Grunebaum, H. (1992). Developing family planning services for female chronic mentally ill outpatients. Hospital and Community Psychiatry, 43, 475-478.
14.
Elia, J., Katz, I. R., & Simpson, G. R. (1987). Teratogenicity of psychotherapeutic medications. Psychopharmacology Bulletin, 23, 531-586.
15.
Entman, S. S., & Vaughn, W. K. (1984). Lack of relation of oral clefts to diazepine use in pregnancy. New England Journal of Medicine, 310, 1121-1122.
16.
Friedman, S., & Harrison, G. (1984). Sexual histories, attitudes, and behavior of schizophrenic and "normal" women. Archives of Sexual Behavior, 13, 555-567.
17.
Gerlach, J. (1991). New antipsychotics: Classification, efficacy, and adverse effects. Schizophrenia Bulletin, 17, 289-309.
18.
Grunebaum, H. U., Abernethy, V. D., & Rofman, E. S. (1971). The family planning attitudes, practices, and motivations of mental patients. American Journal of Psychiatry, 128, 180-182.
19.
Guze, B. H., & Guze, P. A. (1989). Psychotropic medication use during pregnancy. Western Journal of Medicine, 151, 296-298.
20.
Jacobson, S. J., Jones, K., & Johnson, K. (1992). Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet, 339, 530-533.
21.
Janicak, P. G., Davis, J. M., Preskorn, S. H., & Ayd, F. J., Jr. (1993). Principles and practice of psychopharmacology. Baltimore: Williams & Wilkins.
22.
Jones, K. L., Lacro, R. V., Johnson, K. A., & Adams, J. (1989). Pattern of malformations of women treated with carbamazepine during pregnancy. New England Journal of Medicine, 320, 1661-1669.
23.
Laegreid, L., Hagberg, G., & Lundberg, A. (1992a). The effect of benzodiazepines on the fetus and newborn. Neuropediatrics, 23, 18-23.
24.
Laegreid, L., Hagberg, G. & Lundberg, A. (1992b). Neurodevelopment in late infancy after prenatal exposure to benzodiazepines a prospective study. Neuropediatrics, 23, 60-67.
25.
Leguis, E., Jaeken, J., & Eggermont, E. (1987). Sodium valproate, pregnancy, and infantile fatal liver failure. Lancet, 2, 1518-1519.
26.
Marder, S. R., & Van Putten, T. (1995). Antipsychotic medications. In A. F. Schatzberg & C. B. Nemeroff (Eds.), The American Psychiatric Press textbook ofpsychopharmacology (pp. 247-261). Washington, DC: American Psychiatric Press.
27.
Mechanic, D., & Rochefort, D. A. (1992). A policy of inclusion for the mentally ill. Health Affairs, 11, 128-150.
28.
Miller, L. J. (1994). Psychiatric medication during pregnancy: Understanding and minimizing the risks. Psychiatric Annals, 24, 69-75.
29.
Miller, L. J. (1998). Pharmacotherapy during the perinatal period. Essential Psychopharmacology, 2, 263-286.
30.
Misri, S., & Sivertz, K. (1991). Tricyclic drugs in pregnancy and lactation: A preliminary report. International Journal of Psychiatry in Medicine, 21, 157-171.
31.
Mortola, J. F. (1989). The use of psychotropic agents in pregnancy and lactation. Psychiatric Clinics of North America, 12, 69-87.
32.
National Institute of Mental Health. (1986). Client/patient sample survey of inpatient, outpatient, and partial care programs. Rockville, MD: U.S. Department of Health and Human Services, NIMH Survey and Reports Branch, Division of Biometry.
33.
National Institute of Mental Health. (1987). Toward a modelplan for a comprehensive community based mental health system. Rockville, MD: U.S. Department of Health and Human Services, Alcohol, Drug Abuse, and Mental Health Administration.
34.
Nora, J. J., Nora, A. H., & Way, G. I. (1975). Cardiovascular maldevelopment associated with maternal exposure to amantadine. Lancet, 2, 607-607.
35.
Nulman, I., Rovet, J., Stewart, D. E., Wolpin, J., Gardner, H. A., Theis, J. G., Kulin, N., & Koren, G. (1997). Neurodevelopment of children exposed in utero to antidepressant drugs. New England Journal of Medicine, 336, 258-336.
36.
Nurnberg, H. G., & Prudic, J. (1984). Guidelines for treatment of psychosis during pregnancy. Hospital and Community Psychiatry, 35, 67-71.
37.
Packer, S. (1992). Family planning for women with bipolar disorder. Hospital and Community Psychiatry, 43, 479-482.
38.
Robinson, G. E., Stewart, D. E., & Flak, E. (1986). The rational use of psychotropic drugs in pregnancy and postpartum. Canadian Journal of Psychiatry, 31, 183-190.
39.
Rudolph, B., Larson, G. L., Sweeny, S., Hough, E. E., & Arorian, K. (1990). Hospitalized pregnant psychotic women: Characteristics and treatment issues. Hospital and Community Psychiatry, 41, 159-163.
40.
Sachs, M. H., Perry, S., Graver, R., Shindledecker, R., & Hall, S. (1990). Self-reported HIV-related risk behaviors in acute psychiatric inpatients: A pilot study. Hospital and Community Psychiatry, 41, 1253-1255.
41.
Scolnik, D., Nulman, I., Rovet, J.,Gladstone, D., Czuchta, D., Gardner, H. A., Gladstone, R., Ashby, P., Weksberg, R., Einarson, T., & Koren, G. (1994). Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. Journal of the American Medical Association, 271, 767-770.
42.
Schou, M. (1968). Special review: Lithium in psychiatric therapy and prophylaxis. Journal of Psychiatric Research, 6, 67-95.
43.
Schou, M. (1976). What happened to the lithium babies: A follow up of children without malformations. Acta Psychiatrica Scandinavica, 54, 193-197.
44.
Schou, M. (1990). Lithium treatment during pregnancy, delivery and lactation: An update. Journal of Clinical Psychiatry, 51, 410-413.
45.
Spielvogel, A., & Wile, J. (1992). Treatment and outcomes of psychotic patients during pregnancy and childbirth. Birth, 19, 131-137.
46.
St. Clair, S. M., & Schirmer, R. G. (1992). First-trimester exposure to alprazolam. Obstetrics and Gynecology, 80, 843-846.
47.
Stowe, Z. N., & Nemeroff, C. B. (1995). Psychopharmacology during pregnancy and lactation. In A. F. Schatzberg & C. B. Nermeroff (Eds.), The American Psychiatric Press textbook of psychopharmacology (pp. 823-838). Washington, DC: American Psychiatric Press.
48.
Test, M. A., & Berlin, S. B. (1981). Issues of special concern to chronically mentally ill women. Professional Psychology, 12, 136-145.
49.
Verhulst, J., & Schneidman, B. (1981). Schizophrenia and sexual functioning. Hospital and Community Psychiatry, 32, 259-262.
50.
Vorhees, C. V., Minck, D. R., & Berry, H. K. (1988). Anticonvulsants and brain development. Progress in Brain Research, 73, 229-244.
51.
Winter, R. M., Donnai, D., Burn, J., & Tucker, S. M. (1987). Fetal valproate syndrome: Is there a recognisable phenotype?Journal of Medical Genetics, 24, 692-695.
52.
Wisner, K. L., & Perel, J. M. (1988). Psychopharmacologic agents and electroconvulsive therapy during pregnancy and the puerperium. In R. L. Cohen (Ed.), Psychiatric consultation in childbirth settings: Parent and child oriented approaches (pp. 165-206). New York: Plenum Medical Book Co.
53.
Wright, S., Dawling, S., & Ashford, J. J. (1991). Execretion of fluvoxamine in breast milk. British Journal of Clinical Pharmacology, 31, 209-209.
